Search
forResearch 10 of 1000+
- The P&P Hairline Laser: A Novel Hands-Free Laser-Assisted Hairline Device for Hair Restoration Surgery
- P‐79 Hair follicle growth arrest in Austrian Icelandic horses
- The Expression of P-Responsive Genes is Related to Root Hair Growth
- Accumulations of Ca/P in the core of hairs from Taklamakan desert mummies
- Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trial
- 42004 Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study
- Integrating herbal components into pharmaceutical formulations for hair woes
- Phytochemical Constituents and Pharmacology of Eclipta prostrata (L.) L.
- Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study
- Abstract 4350: Pharmacodynamic biomarkers: Evaluation of oncology drug target engagement in human plucked scalp and beard hair
Community 10 of 614
- Phase 3 Study for PP405 officially posted
- Phase 3 for PP405 will now start in 2027
- So why did the first pyrilutamide phase III fail?
- A minoxidil pill just posted strong phase 3 results. Up to 86% of men improved coverage in six months.
- Phase 2B trial for PP405 leaked (The study Pelage DOESN'T want you to see)
- Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
- Pelage PP405: New Hair Growth from Inactive Follicular Units - Phase 2a results at AAD 2026
- TH07 by Triple Hair entering phase III trial
- Phase II topical dut study - outperforms oral fin with a minor DHT reduction
- Pelage to present PP405 Phase 2a clinical trial full results at an upcoming medical meeting - CMO Christina Weng says